Long-acting injectable naltrexone for the treatment of alcohol dependence
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Combining pharmacotherapy with psychosocial and behavioral interventions has helped improve the treatment of alcohol dependence. However, the clinical use of effective medications, such as naltrexone, is limited by poor adherence to a daily oral regimen. Recently, a once monthly extended-release injectable formulation of naltrexone (Vivitrol, Alkermes, Inc.) became the first FDA-approved long-acting formulation of naltrexone for alcohol dependence. Compared with the oral preparation, extended-release naltrexone shows reduced peaks and minimal fluctuations in plasma levels that may possibly lead to a more benign adverse-event profile. The administration of long-acting naltrexone in conjunction with psychosocial support has been associated with significant improvement in drinking outcome measures, especially among patients who are abstinent entering treatment. Additional studies are warranted to increase the knowledge on the clinical applications of long-acting naltrexone in other addictive disorders and to compare extended-release naltrexone with other long-acting formulations that are in development. The clinical availability of extended-release naltrexone has the potential to enhance treatment outcomes for alcohol and other drug dependence disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Saitz, R. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp042262 · Cited by 599
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Harm reduction approaches to alcohol use
Marlatt, G. A., & Witkiewitz, K. (2002) · Addictive Behaviors · doi:10.1016/s0306-4603(02)00294-0 · Cited by 491
How effective is alcoholism treatment in the United States?
Miller, W. R., Walters, S. T., & Bennett, M. E. (2001) · Journal of Studies on Alcohol · doi:10.15288/jsa.2001.62.211 · Cited by 434
The Neurobiology of Substance and Behavioral Addictions
Grant, J. E., Brewer, J. A., & Potenza, M. N. (2006) · CNS Spectrums · doi:10.1017/s109285290001511x · Cited by 372
Measures of Clinical Significance
KRAEMER, H. C., MORGAN, G. A., LEECH, N. L., GLINER, J. A., VASKE, J. J., & HARMON, R. J. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00022 · Cited by 367
Us Public Health Service Clinical Practice Guideline: Treating Tobacco Use and Dependence
Fiore, M. C., & Staff, G. P. A. (2000) · Respiratory Care · doi:10.1177/002013240004501007 · Cited by 346
A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence
Kirchmayer, U., Davoli, M., Verster, A. D., Amato, L., Ferri, A., & Perucci, C. A. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00217.x · Cited by 106
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
Cited by
Intramuscular extended‐release naltrexone: current evidence
Gastfriend, D. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05900.x · Cited by 71
Metadata
- Authors
- Mannelli, P., Peindl, K., Masand, P. S., & Patkar, A. A.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2007-10
- Volume
- 7
- Issue
- 10
- Pages
- 1265-1277
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2034538711
- Cited by
- 183
- References
- 12
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-acting injectable naltrexone for the treatment of alcohol dependence. https://app.cochat.ai/papers/10.1586/14737175.7.10.1265
- The paper
- Mannelli, P., Peindl, K., Masand, P. S., & Patkar, A. A. (2007). Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.7.10.1265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.